The lab will work in areas such as quantum computing, explainable artificial intelligence (AI) that presents data in a manner that can be understood by humans, and Metaverse, a virtual world where people can connect through their digital avatars.
Tech Mahindra already has 10 Makers Lab across the world and the new unit at Mahindra University will be the 11th facility globally and second in Hyderabad, said the company.
“With the launch of Makers Lab, we will provide many talented and skilled individuals, with the opportunity to progress for a greater cause,” said CP Gurnani, MD & CEO, Tech Mahindra.
IT major Tech Mahindra (TechM) and Mahindra University have signed a memorandum of understanding (MoU) to set up a new ‘Makers Lab’ for research and development. The lab will work in areas such as quantum computing, explainable artificial intelligence (AI) that presents data in a manner that can be understood by humans, and Metaverse, a virtual world where people can connect through their digital avatars.
Tech Mahindra already has 10 Makers Lab across the world and the new unit at Mahindra University will be the 11th facility globally and second in Hyderabad, said the company.
“With the launch of Makers Lab, we will provide many talented and skilled individuals, with the opportunity to progress for a greater cause,” said CP Gurnani, MD & CEO, Tech Mahindra.
Part of the cognitive neuroscience bitesize series. This is a follow-up of ‘basics of fMRI’ that considers exciting developments in mapping the human connect…
I promise you: this post is going to tell a scientifically coherent story that involves all five topics listed in the title. Not one can be omitted.
My story starts with a Zoom talk that the one and only Lenny Susskind delivered for the Simons Institute for Theory of Computing back in May. There followed a panel discussion involving Lenny, Edward Witten, Geoffrey Penington, Umesh Vazirani, and your humble shtetlmaster.
Lenny’s talk led up to a gedankenexperiment involving an observer, Alice, who bravely jumps into a specially-prepared black hole, in order to see the answer to a certain computational problem in her final seconds before being ripped to shreds near the singularity. Drawing on earlier work by Bouland, Fefferman, and Vazirani, Lenny speculated that the computational problem could be exponentially hard even for a (standard) quantum computer. Despite this, Lenny repeatedly insisted—indeed, he asked me again to stress here—that he was not claiming to violate the Quantum Extended Church-Turing Thesis (QECTT), the statement th at all of nature can be efficiently simulated by a standard quantum computer. Instead, he was simply investigating how the QECTT needs to be formulated in order to be a true statement.
Dr. Arye Elfenbein, MD, PhD, is the Co-Founder of Wildtype (https://www.wildtypefoods.com/), a biotechnology company which produces cultured seafood (with a focus on cultivated Pacific salmon) from fish cells, sustainably and cost effectively, with the nutritional benefits, but without common contaminants such as mercury, microplastics, antibiotics, or pesticides, and without relying on commercial fishing or fish farming.
Born in Israel and raised in Australia, Dr. Elfenbein combines his deep passion for medicine and unique childhood connection to the ocean to fuel Wildtype’s health and environmental mission.
After studying at Dartmouth and Kyoto University, attaining a PhD and MD, Dr. Elfenbein began his residency at Yale where he first trained in Internal Medicine before completing training in Cardiology. After residency, he moved to San Francisco to work with Professor Dr. Deepak Srivastava at the revered Gladstone Institutes / UCSF, also known for being the scientific homes of Nobel laureates Dr. Shinya Yamanaka (iPs cells) and Dr. Jennifer Doudna (CRISPR).
During his time at the Gladstone Institutes, Dr. Elfenbein’s research focused on cardiac regeneration following heart attacks. This research inspired him to apply the principles of stem cell biology beyond medicine, and to address the growing problems in our food system.
Dr. Amber Salzman, Ph.D. is Chief Executive Officer and Director of Epic Bio (https://epic-bio.com/), a fascinating therapeutic epigenome editing startup, developing therapies to modulate gene expression at the level of the epigenome, which just recently emerged from stealth mode with a $55 million funding round.
Dr. Salzman has more than 30 years of experience in the pharmaceuticals industry. Before joining Epic Bio, Dr. Salzman served as the president and CEO of Ohana Biosciences, pioneering the industry’s first sperm biology platform. Before Ohana, she served as the president and CEO of Adverum Biotechnologies and was a co-founder of Annapurna, SAS, where she served as President and CEO before its merger with Avalanche Biotechnologies to become Adverum. In that role, she saw the company’s stock price double.
Dr. Salzman began her career as a member of the GlaxoSmithKline (GSK) research and development executive team, where she was responsible for operations in drug development across multiple therapeutic areas, overseeing global clinical trials with over 30,000 enrolled patients, managing 1,600 employees and a $1.25B budget.
Following her time at GSK, Dr. Salzman served as the CEO of Cardiokine, a pharmaceutical company that developed treatments for the prevention of cardiovascular diseases and saw the successful sale of the company to Cornerstone Therapeutics.
Sandy and Cory discuss the evolution of Model 3 and Model Y bodies in white over the last five years. Sandy points out the massive advancements that have been made and encourages other OEMs to pursue similar efficiency and lean design.
KELT-9b is an ultra-hot Jupiter planet that orbits an A type star named KELT-9 about 650 light years away. The reason for this insane heat is the intimate proximity the gas giant has to its host star, which is itself among some of the hottest stars we know, reaching temperatures of roughly 9900ºC (17,852ºF).
